MicroSalt PLC projects revenue surge to $15M by 2027, driven by new bulk orders from top-tier customers like a global food giant and Daiya Foods.
This article covers information on MicroSalt PLC.
LON:SALTMicroSalt PLC (AIM: SALT) has put out a compact but meaningful trading update that edges 2025 revenue above plan and strengthens visibility for a sharp ramp in 2026 and 2027. The headline is simple: early bulk orders are now coming through from a top-tier global food and beverage group, while a new deal with Daiya Foods adds another leg of growth.
There is still execution ahead and several moving parts remain non-contractual, but the direction of travel is clear. Here is what changed, why it matters, and what to watch next.
| Metric | Figure |
|---|---|
| 10-month sales to 31 Oct 2025 | $1.66 million |
| FY 2025 revenue | Board expects to exceed $2.0 million (original expectation) |
| Customer 3 2026 sales (North America, new item projection) | Exceeding $5.0 million |
| Customer 3 2027 sales (projection) | $11.0 million |
| Company 2026 projection | $7.0 million |
| Company 2027 projection | More than $15.0 million |
| Daiya initial order | $50,000 |
| Daiya projected 2026 volume | ~$500,000 |
The big swing factor remains Customer 3. In August, MicroSalt flagged increased volume projections from this global player, including a single new item slated for a Q2 2026 North American rollout. Those projections suggested sales exceeding $5.0 million in 2026 and expanding to $11.0 million in 2027 for that product alone.
Today’s update is important because it bridges the gap between talk and traction: MicroSalt has received a first bulk purchase order, destined for a specific end retailer linked to Customer 3, and expects broadly monthly orders from here. While the projections remain non-contractual, regular purchase orders are a tangible signal that the run-up to mid-2026 rollout is under way.
MicroSalt has also signed a non-binding term sheet for a proposed four-year Joint Development Agreement with Customer 3. A JDA is essentially a framework to co-create products and solutions – in this case, new ways to reduce sodium while keeping the familiar salty taste. If finalised, it would deepen the relationship globally and could broaden MicroSalt’s addressable footprint across multiple categories and regions.
Important caveat: the term sheet is non-binding, so investors should watch for conversion into a signed agreement and any detail on scope, exclusivity and milestones, none of which are disclosed today.
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
57 viewsLikes
No ratings yet
On 12 November, MicroSalt announced a strategic relationship with Daiya Foods, a global leader in dairy-free and plant-based products. Daiya has placed an initial $50,000 order, with projected 2026 volume of approximately $500,000. For a company of MicroSalt’s current scale, that is a meaningful contribution and, just as importantly, a strong proof-point in health-led consumer categories where sodium reduction is front and centre.
Between Customer 3 and Daiya, MicroSalt is executing on its B2B bulk strategy – selling ingredient salt directly into branded manufacturers who need to cut sodium without losing taste.
MicroSalt now projects $7.0 million of sales in 2026 and more than $15.0 million in 2027. Management says these numbers are based on in-hand volume estimations and the current customer base. That phrasing matters: it implies the projections are not relying on blue-sky wins, but on volume the company already sees in its pipeline.
The cadence of monthly bulk orders tied to the mid-2026 rollout should be a key driver of that step-change, with the Daiya relationship layering on top. If the JDA is executed and broadens scope, that could support further category expansion.
MicroSalt’s pitch is simple: full-flavour salt with approximately 50% less sodium, delivered via micron-sized particles that increase perceived saltiness. Year to date through 2025, the company says it has contributed to more than 634 million servings made healthier. With regulators and brands focused on sodium reduction, the tailwinds are notable.
The World Health Organisation has targeted a 30% reduction in global sodium intake by 2025, with major health and economic benefits. In the UK alone, cardiovascular disease costs £19 billion annually, and cutting average daily salt by just one gram could save over 4,000 lives and £288 million each year. MicroSalt highlights a defensible IP position too, with a granted US patent and 14 pending applications globally.
This is a constructive update. Moving from projections to a first bulk order, with an expectation of monthly repeats, is the sort of evidence investors wanted ahead of the 2026 ramp. The proposed four-year JDA, even at term sheet stage, signals intent from a blue-chip partner to go deeper on sodium reduction solutions.
On the numbers, exceeding the original $2.0 million revenue expectation for 2025 is a modest positive. The larger story is the projected jump to $7.0 million in 2026 and more than $15.0 million in 2027, now underpinned by visible volume estimations and a new contribution from Daiya Foods.
The flip side is that much remains to be executed: binding contracts, smooth fulfilment, and proof on margins as volumes scale. None of those are unusual risks at this stage, but they matter. If MicroSalt converts the JDA and sustains the monthly order cadence, today’s projections start to feel much more bankable.
MicroSalt’s B2B strategy is starting to convert into recurring orders, with a credible route to a multi-million dollar run-rate in 2026 and beyond. The opportunity is large, the partners are high quality, and the projections are clearer than they were in the summer. Now it is about execution. If management hits the milestones they have outlined, the revenue surge to more than $15.0 million in 2027 looks achievable.
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
No comments yet - start the conversation.